At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions.
Novo Nordisk Canada Inc. is an affiliate of Novo Nordisk A/S, a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions, including hemophilia.
Hemophilia is a rare and serious disease affecting approximately 1:5,000 live male births.1 However, females can be carriers of hemophilia and experience symptoms depending on the concentration of factors.1,2 People living with hemophilia may suffer from chronic pain and limited mobility mainly due to bleeds in the joints; however, modern standards of care in hemophilia recommend multidisciplinary treatment to help manage bleeding, pain, and other complications associated with hemophilia.3
Changing Hemophilia is Novo Nordisk’s commitment to address the unmet needs in hemophilia care. We work towards a future where everyone with hemophilia is diagnosed and can live a life with as few limitations as possible. To learn more about Novo Nordisk’s commitment to Changing Hemophilia, visit our website: https://www.novonordisk.ca/changinghemophilia/html
Acquired hemophilia A is one of the most-rare forms of hemophilia, and often presents in the emergency care setting. Due to the small number of patients living with acquired hemophilia A, this disease is often misdiagnosed. Novo Nordisk is dedicated to increasing awareness about acquired hemophilia A and supporting its diagnosis and treatment.
Explore the links below to learn more about acquired hemophilia A
To learn more about Novo Nordisk and our therapeutic areas, please visit our website: https://www.novonordisk.ca/
For additional information on rare bleeding disorders (RBDs) visit: https://caep.ca/caep-notes/rare-bleeding-disorder/
- Centers for Disease Control. What is Hemophilia? 2020. Available at: https://www.cdc.gov/ncbddd/hemophilia/facts.html. Retrieved November 10, 2020.
- Bolton-Maggs PHB, et al. Haemophilias A and B. The Lancet. 2003;361(9371):1801-1809.
- Srivastava A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158.